8-K: Vivani Medical Advances Semaglutide Implant, Reports 2025 Results

Vivani Medical announced successful preclinical data for its semaglutide implant NPM-139, plans for a Phase 1 study, and reported its Q4 and full-year 2025 financial results.

Summary

• Vivani Medical successfully completed its first-in-human study, LIBERATE-1, demonstrating feasibility of its NanoPortal technology.
• Preclinical data for NPM-139, a semaglutide implant, showed sustained semaglutide exposure and over 20% sham-adjusted weight loss for a full year with a single administration.
• The company is advancing NPM-139 towards a Phase 1 clinical study, anticipated to initiate in mid-2026 in Australia, with results expected by the end of 2026.
• Vivani reported a net loss of $6.6 million for the fourth quarter of 2025, an increase from $6.1 million in Q4 2024.
• The full year 2025 net loss was $26.6 million, up from $23.5 million in 2024.
• Cash and cash equivalents totaled $16.2 million as of December 31, 2025, down from $18.4 million at December 31, 2024, but recent financings of $41.5 million gross proceeds are expected to fund operations into mid-2027.
• Vivani is exploring options for its wholly owned subsidiary, Cortigent Inc., to become an independent, publicly traded company through a spin-off or IPO.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive update. While financial losses increased, the significant preclinical progress with NPM-139 and a solid cash runway into mid-2027 provide a strong foundation for future development in a high-growth market.

Positives

• Successful completion of the LIBERATE-1 first-in-human study, demonstrating a positive safety and tolerability profile and encouraging performance data for the NanoPortal implant technology.
• Strong preclinical proof of concept data for NPM-139 (semaglutide implant) showing sustained semaglutide exposure and over 20% sham-adjusted weight loss for a full year with a single administration, supporting potential for annual dosing.
• Advancement of NPM-139 towards a Phase 1 clinical study, with initiation projected for mid-2026 and results anticipated by the end of 2026.
• Solid cash position of $16.2 million as of December 31, 2025, combined with $41.5 million in gross proceeds from recent financings, is expected to fund operations into mid-2027.
• Strategic focus on the high-growth GLP-1 market with a unique implant candidate offering potential for onceor twice-yearly administration and rapid discontinuation capabilities.
• Significant progress in advancing manufacturing capabilities and clinical operations, including capital equipment purchases and facilities upgrades.

Negatives

• Net loss for the fourth quarter of 2025 increased to $6.6 million, up from $6.1 million in the fourth quarter of 2024.
• Full year 2025 net loss increased to $26.6 million, compared to $23.5 million for the full year 2024.
• Cash and cash equivalents decreased to $16.2 million as of December 31, 2025, from $18.4 million as of December 31, 2024.
• Research and development expenses increased by 15% for the full year 2025 to $18.1 million, primarily due to increased clinical trial and development expenses.
• General and administrative expenses increased by 6% for the full year 2025 to $9.4 million, mainly due to increased professional services.
• Other income, net, decreased by $0.3 million for the full year 2025, partly due to the write-off related to the closure of the Neurostimulation Division's Switzerland subsidiary.

Risks

• Risks that the spin-off of Cortigent will not be completed in a timely manner or at all.
• Risks of failure to satisfy any conditions to the spin-off of Cortigent.
• Risks of failure of the spin-off to qualify for nonrecognition of gain or loss for U.S. federal income tax purposes.
• Uncertainty of whether the anticipated benefits of the spin-off can be achieved.
• Risks of unexpected costs or delays associated with the spin-off process.
• Risks and uncertainties associated with the development and commercialization of products and product candidates that may impact or alter anticipated business plans, strategies, and objectives.
• Risks related to market conditions and the ability of Cortigent to complete its spin-off.
• Cortigent's history of losses and its ability to access additional capital or otherwise fund its business and advance its product candidates and preclinical programs.

Future Outlook

Vivani anticipates initiating its Phase 1 feasibility study for NPM-139 (semaglutide implant) for chronic weight management in mid-2026, with data potentially available by the end of 2026. The company also plans to file an Investigational New Drug Application (IND) for NPM-139 to support a proposed Phase 2 dose-ranging study. Furthermore, Vivani expects to transition Cortigent Inc. into an independent, publicly traded company, exploring both a spin-off and an IPO. Current cash and commitments are projected to fund operations into mid-2027, supporting these key milestones.

Management Comments

• "2025 was a pivotal year for Vivani. We successfully completed our first-in-human study, LIBERATE-1; we demonstrated feasibility of our technology with semaglutide, the active ingredient in Wegovy and Ozempic; and we made progress against strategic decisions that favorably position the Company in the GLP-1 marketplace." Adam Mendelsohn, Ph.D., CEO.
• "Our encouragement was reinforced after having recently demonstrated sustained preclinical semaglutide exposures and >20% sham-adjusted weight loss for a full year with a single implant administration." Adam Mendelsohn, Ph.D., CEO.
• "Our GLP-1 implant candidates are unique because of their potential for both onceor twice-yearly administration and the ability to quickly eliminate GLP-1 levels between scheduled administrations if that became necessary." Adam Mendelsohn, Ph.D., CEO.
• "We project the initiation of our Phase 1 feasibility for NPM-139 (semaglutide implant) for chronic weight management in mid-2026 with data potentially available by the end of this year." Adam Mendelsohn, Ph.D., CEO.

Industry Context

StockSavvy.ai notes that Vivani's focus on semaglutide implants positions it directly within the rapidly expanding GLP-1 agonist market, currently dominated by injectables like Novo Nordisk's Wegovy and Ozempic, and Eli Lilly's Zepbound and Mounjaro. The potential for ultra long-acting, subdermal implants with annual or semi-annual dosing, coupled with the ability for rapid discontinuation, addresses key patient adherence and safety concerns prevalent with existing GLP-1 therapies, potentially offering a significant competitive advantage in a market seeking improved convenience and patient management.

Comparison to Industry Standards

• The filing highlights semaglutide as the active ingredient in market-leading GLP-1 drugs like Wegovy and Ozempic (Novo Nordisk). Vivani's preclinical data demonstrating >20% sham-adjusted weight loss for a full year with a single implant administration sets a high benchmark against the efficacy of existing GLP-1 therapies, which typically require weekly injections.
• The potential for annual dosing with rapid discontinuation capability for NPM-139 could significantly differentiate Vivani's offering from current market leaders by addressing patient adherence challenges and specific medical contraindications (e.g., pregnancy, pre-surgical requirements) more effectively than daily or weekly administrations.

Legal Proceedings

• A litigation accrual of $1,675 thousand is reported on the balance sheet as of December 31, 2025, and December 31, 2024.

Stakeholder Impact

• Shareholders: Potential for value realization through the advancement of NPM-139 and the planned spin-off/IPO of Cortigent. Recent financings have led to an increase in shares outstanding.
• Patients: Potential for a novel, ultra long-acting semaglutide implant offering improved adherence and convenience for chronic weight management and other metabolic diseases.
• Employees: Staffing reduction was mentioned as a factor influencing research and development expenses.
• Creditors: The company's cash runway into mid-2027 and recent capital raises indicate a stable short-to-medium term financial position.

Next Steps

• Initiation of Phase 1 study for NPM-139 (semaglutide implant) in mid-2026.
• Anticipated Phase 1 study results for NPM-139 by the end of 2026.
• Filing of an Investigational New Drug Application (IND) for NPM-139 to support a proposed Phase 2 dose-ranging study.
• Transition of Cortigent Inc. into an independent, publicly traded company, exploring a spin-off (Form 10) or an IPO (Form S-1).
• Continue exploring opportunities for Vivani's stockholders to potentially realize value in its neuromodulation assets (Cortigent).

Key Dates

Recommendation

The company has demonstrated promising preclinical results for its semaglutide implant and has a clear path to Phase 1 clinical trials, which is a significant de-risking event. The strategic focus on the high-growth GLP-1 market and the planned spin-off of Cortigent could unlock value. However, the company is still in early clinical stages, incurring increasing losses, and faces substantial development and regulatory risks. A "Hold" recommendation reflects the potential upside balanced against the inherent risks of a clinical-stage biopharmaceutical company.

Keywords

Semaglutide implant, GLP-1, Weight management, Obesity, NanoPortal technology, Biopharmaceutical, Clinical trial, Phase 1, NPM-139, Vivani Medical, Cortigent, Spin-off, Financial results, SEC filing, 8-K